Skip to main content

Mayo Clinic Licenses Expression Pathology IP

NEW YORK (GenomeWeb News) – Mayo Clinic has acquired a non-exclusive license to Expression Pathology's patent for use in diagnosing systemic amyloidosis in formalin-fixed tissue.

Expression Pathology said today that Mayo Clinic will use the Liquid Tissue patent in a test using mass spectrometric analysis of formalin-fixed paraffin-embedded tissue. Mayo Clinic will offer the test worldwide through its Mayo Medical Laboratories reference laboratory.

The company said that its Liquid Tissue-based method helps physicians make treatment decisions for amyloidosis, which can be localized or systemic, and which can impair organs and cause cardiac or renal failure.

"Detailed mass spectrometry analysis of proteins related to specific disease conditions in FFPE tissue is opening huge opportunities in personalized medicine to relate those measurements to patient treatment decisions," Expression Pathology President and CEO Casey Eitner said today.

Financial terms of the agreement were not released.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.